Your browser doesn't support javascript.
loading
Prevalence of high-penetrant copy number variants in 7734 low-risk pregnancies.
Sagi-Dain, Lena; Salzer Sheelo, Liat; Brabbing-Goldstein, Dana; Matar, Reut; Kahana, Sarit; Agmon-Fishman, Ifaat; Klein, Cochava; Gurevitch, Merav; Basel-Salmon, Lina; Maya, Idit.
Affiliation
  • Sagi-Dain L; Genetics Institute, Carmel Medical Center, affiliated to the Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel (XX Sagi-Dain). Electronic address: lena2303@gmail.com.
  • Salzer Sheelo L; Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel (XX Sheelo, XX Brabbing-Goldstein, XX Matar, XX Kahana, XX Agmon-Fishman, XX Klein, XX Gurevitch, XX Basel-Salmon, and XX Maya).
  • Brabbing-Goldstein D; Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel (XX Sheelo, XX Brabbing-Goldstein, XX Matar, XX Kahana, XX Agmon-Fishman, XX Klein, XX Gurevitch, XX Basel-Salmon, and XX Maya).
  • Matar R; Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel (XX Sheelo, XX Brabbing-Goldstein, XX Matar, XX Kahana, XX Agmon-Fishman, XX Klein, XX Gurevitch, XX Basel-Salmon, and XX Maya).
  • Kahana S; Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel (XX Sheelo, XX Brabbing-Goldstein, XX Matar, XX Kahana, XX Agmon-Fishman, XX Klein, XX Gurevitch, XX Basel-Salmon, and XX Maya).
  • Agmon-Fishman I; Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel (XX Sheelo, XX Brabbing-Goldstein, XX Matar, XX Kahana, XX Agmon-Fishman, XX Klein, XX Gurevitch, XX Basel-Salmon, and XX Maya).
  • Klein C; Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel (XX Sheelo, XX Brabbing-Goldstein, XX Matar, XX Kahana, XX Agmon-Fishman, XX Klein, XX Gurevitch, XX Basel-Salmon, and XX Maya).
  • Gurevitch M; Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel (XX Sheelo, XX Brabbing-Goldstein, XX Matar, XX Kahana, XX Agmon-Fishman, XX Klein, XX Gurevitch, XX Basel-Salmon, and XX Maya).
  • Basel-Salmon L; Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel (XX Sheelo, XX Brabbing-Goldstein, XX Matar, XX Kahana, XX Agmon-Fishman, XX Klein, XX Gurevitch, XX Basel-Salmon, and XX Maya); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (XX Basel-Sa
  • Maya I; Recanati Genetics Institute, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel (XX Sheelo, XX Brabbing-Goldstein, XX Matar, XX Kahana, XX Agmon-Fishman, XX Klein, XX Gurevitch, XX Basel-Salmon, and XX Maya); Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (XX Basel-Sa
Am J Obstet Gynecol MFM ; 5(12): 101201, 2023 12.
Article in En | MEDLINE | ID: mdl-37871696
ABSTRACT

BACKGROUND:

The rate of clinically significant copy number variants in chromosomal microarray analysis in low-risk pregnancies is approximately 1%. However, these results include copy number variants with low and variable penetrance, although some patients might be interested only in the detection of high-penetrant variants.

OBJECTIVE:

This study aimed to calculate the prevalence of high-penetrant copy number variants in a large cohort of low-risk pregnancies. STUDY

DESIGN:

This retrospective study was performed using microarray results of pregnancies with normal ultrasound and maternal serum screening. All clinically significant (pathogenic and likely pathogenic) copy number variants were recorded. Of these, only high-penetrant findings were selected. Findings with low and medium penetrance and copy number variants with unknown clinical penetrance, including uniparental disomy of segments not related to known imprinted syndromes, mosaic aneuploidy of <50%, and segmental mosaicism, were excluded. The calculation was performed for the overall cohort, for women aged >35 years and women aged <35 years, and after omission of noninvasive prenatal screening theoretically detectable findings (trisomies 13, 18, and 21).

RESULTS:

Clinically significant copy number variants were detected in 118 of 7734 cases (1.50% or 165), and high-penetrant copy number variants were detected in 33 of 7734 cases (0.43% or 1234). In women aged ≥35 years, the rates of high-penetrant copy number variants were 29 of 5734 cases (0.51% or 1198) and 4 of 2000 cases (0.20% or 1500) in women aged <35 years (P=.0747). Following the omission of 12 theoretically noninvasive prenatal screening-detectable findings, the rates of high-penetrant copy number variants declined to 21 of 7722 cases (0.27% or 1368) in the whole cohort-18 of 5723 cases (0.31% or 1318) in woman aged ≥35 years and 3 of 1999 cases (0.15% or 1666) in younger women (P=.319).

CONCLUSION:

The risk of high-penetrant copy number variants in low-risk pregnancies exceeds the risk of miscarriage after invasive testing, even after normal noninvasive prenatal screening results. These results are of importance to genetic counselors and obstetricians, to facilitate maternal informed decision-making when considering invasive prenatal testing in low-risk pregnancies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prenatal Diagnosis / DNA Copy Number Variations Limits: Female / Humans / Pregnancy Language: En Journal: Am J Obstet Gynecol MFM Year: 2023 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prenatal Diagnosis / DNA Copy Number Variations Limits: Female / Humans / Pregnancy Language: En Journal: Am J Obstet Gynecol MFM Year: 2023 Type: Article